Chembio Diagnostics Reports Third Quarter 2020 Financial Results

HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2020.

Recent Accomplishments & Highlights

  • Achieved total revenue of $10.3 million and product revenue of $8.4 million for the third quarter of 2020, representing growth of 6% and a decrease of 1% respectively, compared to the prior year period
  • Submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the DPP SARS-CoV-2 Antigen test system, which was funded with the support of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under Contract No. 75A50120C00138
  • Submitted an EUA application to the FDA for the DPP SARS-CoV-2 IgM/IgG test system
  • Received FDA Pre-Market Approval (PMA) for the DPP HIV-Syphilis System, the first rapid test approved in the U.S. to aid in diagnosis of both HIV and Syphilis from single patient sample

“Over the past months we have executed our COVID-19 product development and regulatory strategy ahead of our expectations. The potential launch of antigen and antibody test systems that leverage the DPP platform will provide much needed and expanded access to decentralized COVID-19 testing amid the resurgance of cases across the U.S. Running both types of tests on the same Micro Reader analyzer will enable clinicians to address the needs of a broader patient population throughout all phases of the pandemic,” said Richard Eberly, Chembio’s President and Chief Executive Officer. “Our third quarter results demonstrate improvement in total revenues, which include revenue from DPP COVID-19 IgM/IgG systems shipped outside the U.S. in the second quarter.”

“We have significantly expanded our U.S commercial team with experienced industry professionals and are continuing to do so. We are also actively launching the DPP HIV-Syphilis System,” Mr. Eberly continued. “Looking forward, we are excited about Chembio’s future, serving multiple end markets that combined represent the most significant opportunity in the company’s history.”

Third Quarter 2020 Financial Results
Total revenue for the third quarter of 2020 was $10.3 million, an increase of 6% compared to the prior year period. Net product sales for the third quarter of 2020 were $8.4 million, a decrease of 1% compared to the prior year period. License and royalty revenue and R&D and grant revenue for the third quarter of 2020 totaled $1.9 million, an increase of 54% compared to the prior year period.

Gross product margin for the third quarter of 2020 was $0.9 million, compared to $1.9 million for the prior year period. Gross product margin percentage for the third quarter of 2020 was 11.2%, compared to 21.9% for the prior year period. Gross product margin in the third quarter of 2020 was impacted by a high concentration of sales outside the U.S. where average selling prices are lower, and operational inefficiencies, including those triggered by the recall of products starting at the end of the second quarter of 2020 together with activities related to qualifying automated manufacturing lines.

Research and development expenses increased by $0.1 million, or 6%, in the third quarter of 2020 compared to the prior year period. Selling, general and administrative expenses increased by $0.9 million, or 20%, in the third quarter of 2020 compared to the prior year period.

Net loss for the third quarter of 2020 was $5.5 million, or $0.28 per diluted share, compared to a net loss of $3.8 million, or $0.22 per diluted share, for the prior year period. 

Cash and cash equivalents as of September 30, 2020 totaled $28.7 million.

Conference Call
Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights. Investors interested in listening to the call may do so by dialing 844-602-0380 from the United States or 862-298-0970 from outside the United States. To listen to a live webcast of the call, please visit the Investor Relations section of Chembio's website at Following the call, a replay will be available on the Investor Relations section of Chembio’s website for 90 days. A telephone replay will be available until 4:30 pm ET on November 19, 2020 by dialing 877-481-4010 from the United States or 919-882-2331 from outside the United States and using the conference ID: 38202.

About the DPP Rapid Test Platform
Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, Agência Nacional de Vigilância Sanitária (ANVISA), and other global organizations, where they aid in the detection and diagnosis of several other critical diseases and conditions.

All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at

Forward-Looking Statements
Certain statements contained in the first paragraph following the bulleted items under “Recent Accomplishments & Highlights: above are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the availability and functionality of COVID-19 tests. Such statements, which are expectations only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events or performance may differ materially from forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the following, any of which could be exacerbated even further by the continuing COVID-19 outbreak in the United States and globally: the ability of Chembio to maintain existing, and timely obtain additional, regulatory approvals, particularly for its proposed DPP COVID-19 diagnostic tests; Chembio’s dependence upon, and limited experience with, COVID-19 diagnostic tests; the highly competitive and rapidly developing market for testing solutions for COVID-19, which includes a number of competing companies with strong relationships with current and potential customers, including governmental authorities, and with significantly greater financial and other resources that are available to Chembio; and the risks of doing business with foreign governmental entities, including geopolitical, international and other challenges as well as potential material adverse effects of tariffs and other changes in U.S. trade policy. Chembio undertakes no obligation to publicly update forward-looking statements in this release to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to the forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's public filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its subsequent Quarterly Reports on Form 10-Q, particularly under the heading “Risk Factors.”

DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Investor Relations Contact
Philip Taylor
Gilmartin Group
(415) 937-5406

 For the three months ended  For the nine months ended
 September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019
Net product sales$ 8,406,457   $8,510,629  $ 17,914,623   $23,381,906 
R&D and grant revenue  1,654,500    971,980    3,756,161    3,528,033 
License and royalty revenue  211,521    238,330    572,450    703,352 
TOTAL REVENUES  10,272,478    9,720,939    22,243,234    27,613,291 
Cost of product sales  7,467,746    6,649,114    17,512,925    18,112,676 
Research and development expenses  2,351,880    2,223,939    6,233,040    6,542,591 
Selling, general and administrative expenses  5,348,958    4,455,588    13,903,192    12,565,601 
Severance, restructuring and other related costs  11,651    -    1,122,310    - 
Acquisition Costs  -    -    63,497    395,612 
   15,180,235    13,328,641    38,834,964    37,616,480 
LOSS FROM OPERATIONS (4,907,757)  (3,607,702)   (16,591,730)  (10,003,189)
Interest Expense, net (735,819)  (195,970)  (2,110,011)  (183,368)
LOSS BEFORE INCOME TAXES  (5,643,576)  (3,803,672)   (18,701,741)  (10,186,557)
Income tax benefit  104,778    20,667    319,597    400,339 
NET LOSS$ (5,538,798) $(3,783,005) $ (18,382,144) $(9,786,218)
Basic and diluted loss per share$ (0.28) $(0.22) $ (0.98) $(0.58)
Weighted average number of shares outstanding, basic and diluted  20,104,547    16,923,695    18,728,372    16,912,583 

 September 30, 2020 December 31, 2019
- ASSETS -   
Cash and cash equivalents$ 28,687,453   $18,271,352 
Accounts receivable, net of allowance for doubtful accounts of $276,210 and $62,000 as of September 30, 2020 and December 31, 2019, respectively  3,522,498    3,661,325 
Inventories, net  12,363,486    9,598,030 
Prepaid expenses and other current assets  1,007,473    693,013 
TOTAL CURRENT ASSETS  45,580,910    32,223,720 
Property, Plant and Equipment, net  8,033,112    5,933,569 
Finance lease right-of-use asset, net  248,892    210,350 
TOTAL FIXED ASSETS, net  8,282,004    6,143,919 
Operating lease right-of-use assets, net  6,316,221    7,030,744 
Intangible assets, net  3,648,495    3,914,352 
Goodwill  5,696,679    5,872,690 
Deposits and other assets  462,664    543,539 
TOTAL ASSETS$ 69,986,973   $55,728,964 
Accounts payable and accrued liabilities$ 6,558,782   $5,526,243 
Deferred revenue  3,865,754    125,000 
Finance lease liabilities  57,715    41,894 
Operating lease liabilities  710,535    568,294 
Note payable  -    180,249 
TOTAL CURRENT LIABILITIES  11,192,786    6,441,680 
Long-term operating lease liabilities  6,448,515    6,969,603 
Long-term finance lease liabilities  200,397    171,953 
Long-term debt, less current portion, net  18,040,427    17,644,149 
Deferred tax liability  165,326    466,326 
TOTAL LIABILITIES  36,047,451    25,252,031 
Preferred stock – 10,000,000 shares authorized, none outstanding  -    - 
Common stock - $0.01 par value; 100,000,000 shares authorized; 20,213,956 shares and 17,733,617 shares issued at September 30, 2020 and December 31, 2019, respectively  202,139    177,335 
Additional paid-in capital  124,622,252    95,433,077 
Accumulated deficit  (89,967,147)  (71,585,003)
Treasury stock 33,290 and 0 shares at cost as of September 30, 2020 and December 31, 2019, respectively  (150,919)  - 
Accumulated other comprehensive (loss) income  (766,803)  9,844 
TOTAL STOCKHOLDERS’ EQUITY  33,939,522    24,035,253 

 For the nine months ended
 September 30, 2020 September 30, 2019
Net cash used in operating activities$ (14,146,887) $(6,398,207)
Net cash used in investing activities  (3,182,180)  (2,769,147)
Net cash provided by financing activities  27,870,382    18,517,604 
Effect of exchange rate changes on cash  (125,214)  (6,909)
Cash and cash equivalents - beginning of the period  18,271,352    12,524,551 
Cash and cash equivalents - end of the period$ 28,687,453   $21,867,892 

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.